Terms: = Lung cancer AND FLT3, STK1, 2322, ENSG00000122025, P36888, FLK2, CD135, RP11-153M24_3 AND Clinical Outcome
924 results:
1. Effect of body mass index and cholesterol-rich apolipoprotein-B-containing lipoproteins on clinical outcome in NSCLC patients treated with immune checkpoint inhibitors-based therapy: A retrospective analysis.
Hu Z; Zheng Y; Zheng J; Wang Y; Liao J; Liu Z; Li J; Cui H
Cancer Med; 2024 Jun; 13(11):e7241. PubMed ID: 38819098
[TBL] [Abstract] [Full Text] [Related]
2. KRAS Allelic Variants in Biliary Tract cancers.
Moffat GT; Hu ZI; Meric-Bernstam F; Kong EK; Pavlick D; Ross JS; Murugesan K; Kwong L; De Armas AD; Korkut A; Javle M; Knox JJ
JAMA Netw Open; 2024 May; 7(5):e249840. PubMed ID: 38709532
[TBL] [Abstract] [Full Text] [Related]
3. clinical and Imaging Characteristics of SARS-CoV-2 Breakthrough Infection in Hospitalized Immunocompromised Patients.
Lee JE; Kim J; Hwang M; Kim YH; Chung MJ; Jeong WG; Jeong YJ
Korean J Radiol; 2024 May; 25(5):481-492. PubMed ID: 38627873
[TBL] [Abstract] [Full Text] [Related]
4. Remote Monitoring and Data Collection for Decentralized clinical Trials.
Daly B; Brawley OW; Gospodarowicz MK; Olopade OI; Fashoyin-Aje L; Smart VW; Chang IF; Tendler CL; Kim G; Fuchs CS; Beg MS; Zhang L; Legos JJ; Duran CO; Kalidas C; Qian J; Finnegan J; Pilarski P; Keane H; Shen J; Silverstein A; Wu YL; Pazdur R; Li BT
JAMA Netw Open; 2024 Apr; 7(4):e246228. PubMed ID: 38607626
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic impact of age in advanced non-small cell lung cancer patients undergoing first-line checkpoint inhibitor immunotherapy and chemotherapy treatment.
Huang X; Wu S; Chen S; Qiu M; Zhao Y; Wei J; He J; Zhao W; Tan L; Su C; Zhou S
Int Immunopharmacol; 2024 May; 132():111901. PubMed ID: 38554448
[TBL] [Abstract] [Full Text] [Related]
6. clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR-mutated advanced non-small-cell lung.
Kuo CY; Tsai MJ; Hung JY; Lee MH; Wu KL; Tsai YC; Chuang CH; Huang CW; Chen CL; Yang CJ; Chong IW
Kaohsiung J Med Sci; 2024 May; 40(5):467-476. PubMed ID: 38523603
[TBL] [Abstract] [Full Text] [Related]
7. Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer.
Haratani K; Nakamura A; Mamesaya N; Sawa K; Shiraishi Y; Saito R; Tanizaki J; Tamura Y; Hata A; Tsuruno K; Sakamoto T; Teraoka S; Oki M; Watanabe H; Tokito T; Nagata K; Masuda T; Nakamura Y; Sakai K; Chiba Y; Ito A; Nishio K; Yamamoto N; Nakagawa K; Hayashi H
Br J Cancer; 2024 May; 130(11):1783-1794. PubMed ID: 38519705
[TBL] [Abstract] [Full Text] [Related]
8. Spreading Through Air Spaces And Thinking About lung Metastases.
M Castro P; Rei J; Silva C; Miranda J; Guerra M
Port J Card Thorac Vasc Surg; 2023 Oct; 30(3):31-35. PubMed ID: 38499034
[TBL] [Abstract] [Full Text] [Related]
9. C-Myc protein expression indicates unfavorable clinical outcome in surgically resected small cell lung cancer.
Lang C; Megyesfalvi Z; Lantos A; Oberndorfer F; Hoda MA; Solta A; Ferencz B; Fillinger J; Solyom-Tisza A; Querner AS; Egger F; Boettiger K; Klikovits T; Timelthaler G; Renyi-Vamos F; Aigner C; Hoetzenecker K; Laszlo V; Schelch K; Dome B
World J Surg Oncol; 2024 Feb; 22(1):57. PubMed ID: 38369463
[TBL] [Abstract] [Full Text] [Related]
10. Dynamic immune signatures of patients with advanced non-small-cell lung cancer for infection prediction after immunotherapy.
Luo YH; Shen CI; Chiang CL; Huang HC; Chen YM
Front Immunol; 2024; 15():1269253. PubMed ID: 38343550
[TBL] [Abstract] [Full Text] [Related]
11. A novel investigation into the negative impact of opioid use on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
Guo H; Li Y; Lin J; Li D; Yang J; Wang J; Mao J; Wang Y; Yan X
Int Immunopharmacol; 2024 Mar; 129():111611. PubMed ID: 38325047
[TBL] [Abstract] [Full Text] [Related]
12. Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC.
Liu JS; Cai YX; He YZ; Xu J; Tian SF; Li ZQ
BMC Cancer; 2024 Jan; 24(1):123. PubMed ID: 38267913
[TBL] [Abstract] [Full Text] [Related]
13. Bacteria and bacteriophage consortia are associated with protective intestinal metabolites in patients receiving stem cell transplantation.
Thiele Orberg E; Meedt E; Hiergeist A; Xue J; Heinrich P; Ru J; Ghimire S; Miltiadous O; Lindner S; Tiefgraber M; Göldel S; Eismann T; Schwarz A; Göttert S; Jarosch S; Steiger K; Schulz C; Gigl M; Fischer JC; Janssen KP; Quante M; Heidegger S; Herhaus P; Verbeek M; Ruland J; van den Brink MRM; Weber D; Edinger M; Wolff D; Busch DH; Kleigrewe K; Herr W; Bassermann F; Gessner A; Deng L; Holler E; Poeck H
Nat Cancer; 2024 Jan; 5(1):187-208. PubMed ID: 38172339
[TBL] [Abstract] [Full Text] [Related]
14. Sarcomas With RAD51B Fusions Are Associated With a Heterogeneous Phenotype.
Chang HY; Dermawan J; Sharma A; Dickson B; Turashvili G; Torrence D; Nucci M; Chiang S; Oliva E; Kirchner M; Stenzinger A; Mechtersheimer G; Antonescu C
Mod Pathol; 2024 Feb; 37(2):100402. PubMed ID: 38141829
[TBL] [Abstract] [Full Text] [Related]
15. Circulating Immune Proteins: Improving the Diagnosis and clinical outcome in Advanced Non-Small Cell lung cancer.
Torres-Martínez S; Calabuig-Fariñas S; Gallach S; Mosqueda M; Munera-Maravilla E; Sirera R; Navarro L; Blasco A; Camps C; Jantus-Lewintre E
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139416
[TBL] [Abstract] [Full Text] [Related]
16. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
[TBL] [Abstract] [Full Text] [Related]
17. [clinical analysis of lung adenocarcinoma with epidermal growth factor receptor mutation transformed into sarcoma].
Zhu QQ; Du MZ; Wu WT; Guo LC; Huang JA; Shen D
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Jan; 47(1):24-30. PubMed ID: 38062690
[No Abstract] [Full Text] [Related]
18. Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy.
Lin R; Mallick AB; Wang ZX; Brown SA; Lu B; Jiang W
Diagn Pathol; 2023 Oct; 18(1):116. PubMed ID: 37865792
[TBL] [Abstract] [Full Text] [Related]
19. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse outcomes in Patients With EGFR-Mutant lung cancer.
Stockhammer P; Grant M; Wurtz A; Foggetti G; Expósito F; Gu J; Zhao H; Choi J; Chung S; Li F; Walther Z; Dietz J; Duffield E; Gettinger S; Politi K; Goldberg SB
J Thorac Oncol; 2024 Feb; 19(2):240-251. PubMed ID: 37806385
[TBL] [Abstract] [Full Text] [Related]
20. Thyroid transcription factor-1 expression in lung neuroendocrine tumours: a gender-related biomarker?
La Salvia A; Siciliani A; Rinzivillo M; Verrico M; Baldelli R; Puliani G; Modica R; Zanata I; Persano I; Fanciulli G; Bassi M; Mancini M; Bellino S; Giannetta E; Ibrahim M; Panzuto F; Brizzi MP; Faggiano A
Endocrine; 2024 Feb; 83(2):519-526. PubMed ID: 37775725
[TBL] [Abstract] [Full Text] [Related]
[Next]
